How are treatment decisions evolving for high-risk NMIBC in the era of BCG shortage and expanding options? Dr. Sima Porten and Dr. Patrick Hensley join Dr. Vignesh Packiam to discuss counseling newly diagnosed patients amid the ongoing BCG shortage and the rise of alternate

Grateful to have @DrMBWesterman on our @UNCUroOnc team, leading work locally and nationally in multiple dimensions (here as co-Chair of spectacular @UroOnc #SUO25 winter meeting) 🤩🙏🚀🚀🚀

@saumyg shares his journey on obtaining @SUO_YUO CTC grant highlighting his mentors and colleagues through this successful path! #SUO2025 @UroOnc

Trial updates in intermediate risk #NMIBC. Presentation by @VigneshPackiam @RutgersCancer. #SUO25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/hQCxAPnPp6 @UroOnc #SUO2025

Thank you @spsutkaMD @KSMurrayUro @VigneshPackiam for discussing the 2025 @EurUrolOpen validation study on Decipher Bladder during Episode 271 of @_backtableUro cc @Uroweb @AmerUrological @urotoday @IBCN1997 @Veracyte @Davicioni https://t.co/YsvIo6J4od

New therapies and biomarkers are opening up paths for patients with recurrent NMIBC. @MarkTysonMD @spsutkaMD and @VigneshPackiam break down how evolving options are reshaping care #URO275 @ferring https://t.co/sn3Lor3BXm

Amazing evening showcasing our world-class #bladdercancer program @RutgersCancer Improving the care, longevity & QOL for our patients through bench-to-bedside research Grateful to our patients & supporters! @saumyg @VigneshPackiam @IBCG_BladderCA @BladderCancerUS @NYSAUA @UroOnc

Exciting times for NMIBC patients. Big improvements coming for doublet therapy administration. Will allow for ⬆️ adoption of these protocols at other facilities by ⬇️ in room time. @VigneshPackiam @HougenHY @AmandaMyersMD @TheBigLoeb @uroHenning

Could biomarkers and AI help move bladder cancer care beyond routine cystoscopy? In part five of our NMIBC Creator Weekend™ series, @spsutkaMD @KSMurrayUro and @VigneshPackiam discuss the future of genomics and decision-making in NMIBC @ferring #URO271 https://t.co/rJSXMjhqpm

Great pod ⁦@VigneshPackiam⁩ thank you

Awesome work by @IanMcelree, @HougenHY @VigneshPackiam & the Iowa UCC squad looking at multiple lines of salvage therapy for NMIBC. Low rate of progression. Many can be salvaged! Need better biomarkers to figure out who gets continued salvage vs Cx.

Very excited to share this project >2 years in the making! Drug-releasing intravesical floating technology (DRIFT) allowing for synchronous delivery yet sequential exposure Could help existing and novel combination regimens! @BladderCancerUS @SUO_YUO @IBCG_BladderCA

Almost every case we find something occult on blue light that is subtle or missed on white Hard to believe that would not have a positive impact on outcomes (especially with NMIBC outcomes broadly improving in trials/centers of excellence) @RutgersCancer @saumyg

1/4 IMVIGOR011 shows ctDNA is a useful predictive and prognostic tool post cystectomy in muscle invasive bladder cancer #ESMO25 . ctDNA positive patients had DFS and OS benifits with atezolizumab. ctDNA negative patients are at a low risk of relapse/cancer death. @OncoAlert

How do you tailor NMIBC care to the individual, not just the disease? In Episode 2 of our NMIBC Creator Weekend™ series, @SimaPorten @pjhensley11 and @VigneshPackiam discuss patient-centered approaches in bladder cancer care @Ferring #URO266 https://t.co/yZpMJCneJR

Incredible accomplishment to complete these studies!!! IMO not worth it for almost all patients to be subject to high grade IO toxicity risk for a 5% 2-year benefit (primarily with recurrence not progression)

🔥@UrolOncol: November issue! Comparative outcomes of radical nephroureterectomy and kidney-sparing surgery in the treatment of high-grade upper tract urothelial carcinoma Click here to read the #OpenAccess article ▶️ https://t.co/2JSrirqWVR

Great 🧵 on an important paper and topic. Now that there are multiple options for BGC-U NMIBC, need to find a way to sequence them. Cost will be an important piece of that. Lucky to have @AmandaMyersMD at @UIowa_urology continuing this great work!

Season 3 of BackTable Tumor Board is LIVE! Our 8-episode deep dive into the complete management of Non-Muscle Invasive Bladder Cancer. This season is your guide to the latest strategies, from diagnosis to advanced therapeutics. Across the season we cover the entire spectrum of